AI assistant
ACRUX LIMITED — Call Transcript 2017
Feb 13, 2017
64293_rns_2017-02-13_16e86d9e-81d0-4236-a7f6-14e7800978ab.pdf
Call Transcript
Open in viewerOpens in your device viewer
ACRUX (ACR) - ASX ANNOUNCEMENT
14 FEBRUARY 2017
HALF-YEAR INVESTOR CONFERENCE CALL – UPDATED DIAL IN DETAILS
==> picture [482 x 10] intentionally omitted <==
Acrux (ASX: ACR) advises of changed dial-in phone numbers provided by its conference call service provider. Below are the updated details for the conference call to discuss the results for the half-year ended 31 December 2016.
Investor Conference Call details:
Date: Tuesday 21 February 2017 Time: 10:00am (AEDT)
Conference ID: 5034 5465
Dial-in phone numbers: Australia toll free phone number: 1800 123 296 Australia: +61 2 8038 5221 New Zealand: 0800 452 782 Singapore: 800 616 2288 United States: 1855 293 1544 United Kingdom: 0808 234 0757
A Q&A session will be held following the Company presentation. Shareholders and analysts are encouraged to participate by forwarding questions to [email protected] in advance of the conference call.
Acrux recommends participants dial in prior to the commencement of the call. A recording of the call will be made available in the ‘Investor Centre’ section of the Company website at: http://www.acrux.com.au/
For further information, contact
Michael Kotsanis, CEO and Managing Director: 03 8379 0100
Tim Bateman, CFO and Company Secretary: 03 8379 0100
==> picture [563 x 93] intentionally omitted <==
About Acrux
Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron[®] , Evamist[®] and Lenzetto[®] . More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its onsite laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.
For further information on Acrux, visit www.acrux.com.au
==> picture [551 x 84] intentionally omitted <==